

Haematologica
HAEMATOL/2017/163816
Version 2

Inclusion and response criteria for clinical trials in relapsed / refractory acute lymphoblastic leukemia and usefulness of historical control trials

Nicola Goekbuget, Herve Dombret, Renato Bassan, Martha Wadleigh,
Michael Doubek, and Josep Ribera

Disclosures: N.G. has received research support and honoraria from Pfizer and Amgen. The remaining authors declare no competing financial interests.

Contributions: NG wrote the first draft of the manuscript; all authors reviewed and approved the manuscript and made the decision to submit the manuscript for publication.